UBS/CALL/BB BIOTECH N/55.003/0.0333/20.12.24 | Market Closed - Swiss Exchange 11:20:00 2024-04-05 EDT | ||
| 0.02 CHF | -33.33% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BB BIOTECH AG
Static data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BB BIOTECH AG |
| Issuer | UBS |
| UBIOVU | |
| ISIN | CH1329014430 |
| Date issued | 2024-03-04 |
| Strike | 55 CHF |
| Maturity | 2024-12-20 (218 Days) |
| Parity | 30 : 1 |
| Emission price | 0.03 CHF |
| Emission volume | N/A |
| Settlement | physical |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.05 CHF |
|---|---|
| Lowest since issue | 0.02 CHF |
| Spread | 0.01 CHF |
| Spread % | 50.00% |
Company Profile
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Sector
-
Consensus: BB Biotech AG
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
41.75
CHF
Average target price
47.7
CHF
Spread / Average Target
+14.25%
- Stock Market
- Warrants
- UBIOVU Warrant
